Drug Trial Radar · NCT00141323
Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)
Last checked: Nov 19, 2026Latest source record: Aug 15, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,556
Planned (sponsor's estimate)
Start
Nov 2001
Primary completion
Dec 2007
Study completion Dec 2007
Sponsor
- Lead sponsor
- Ligand PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 1, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 60 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine the safety and effectiveness of 2 doses of the investigational drug, lasofoxifene, compared to placebo (an inactive substance) in reducing new spinal fractures in women with osteoporosis.
Conditions
- Osteoporosis
Interventions
lasofoxifeneDrug
0.5 mg once per day, orally
placeboOther
placebo
lasofoxifeneDrug
0.25 mg once per day, orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- New morphometric vertebral fracturesTime frame: 3 years
- New cases of breast cancerTime frame: 5 years
- New non-vertebral fracturesTime frame: 5 years
Locations
201 sites in 32 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
La Jolla, California
Pfizer Investigational Site
La Jolla, California
Pfizer Investigational Site
La Jolla, California
Pfizer Investigational Site
Palm Desert, California
Pfizer Investigational Site
Palm Springs, California
Pfizer Investigational Site
Palm Springs, California
Pfizer Investigational Site
Poway, California
Pfizer Investigational Site
Rancho Mirage, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
Brandon, Florida
Pfizer Investigational Site
Leesburg, Florida
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
West Palm Beach, Florida
Pfizer Investigational Site
Des Plaines, Illinois
Pfizer Investigational Site
Morton Grove, Illinois
Pfizer Investigational Site
Des Moines, Iowa
Pfizer Investigational Site
Bethesda, Maryland
Pfizer Investigational Site
Montgomery Village, Maryland
Pfizer Investigational Site
Arden Hills, Minnesota
Pfizer Investigational Site
Minneapolis, Minnesota
Pfizer Investigational Site
Omaha, Nebraska
Pfizer Investigational Site
Albuquerque, New Mexico
Pfizer Investigational Site
Albuquerque, New Mexico
Pfizer Investigational Site
Centerville, Ohio
Pfizer Investigational Site
Dayton, Ohio
Pfizer Investigational Site
Portland, Oregon
Pfizer Investigational Site
Charleroia, Pennsylvania
Pfizer Investigational Site
Monessen, Pennsylvania
Pfizer Investigational Site
Cordova, Tennessee
Pfizer Investigational Site
Memphis, Tennessee
Pfizer Investigational Site
Dallas, Texas
Pfizer Investigational Site
San Antonio, Texas
Pfizer Investigational Site
Richmond, Virginia
Pfizer Investigational Site
Richmond, Virginia
Pfizer Investigational Site
Richmond, Virginia
Showing 40 of 201 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.